6,205 Shares of Charles River Laboratories International, Inc. $CRL Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the third quarter, HoldingsChannel reports. The institutional investor purchased 6,205 shares of the medical research company’s stock, valued at approximately $1,831,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. boosted its holdings in Charles River Laboratories International by 127.9% during the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 55 shares in the last quarter. Continuum Advisory LLC acquired a new position in shares of Charles River Laboratories International in the 2nd quarter worth approximately $30,000. IFP Advisors Inc raised its holdings in shares of Charles River Laboratories International by 182.8% in the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after buying an additional 106 shares in the last quarter. Compass Wealth Management LLC acquired a new position in shares of Charles River Laboratories International in the 3rd quarter worth approximately $69,000. Finally, Activest Wealth Management lifted its position in shares of Charles River Laboratories International by 25.9% during the 3rd quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after buying an additional 57 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently commented on CRL shares. TD Cowen reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday. UBS Group increased their price objective on Charles River Laboratories International from $357.00 to $387.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Jefferies Financial Group lifted their price objective on Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a report on Monday, September 28th. Royal Bank Of Canada lifted their price objective on Charles River Laboratories International from $322.00 to $352.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Finally, Robert W. Baird boosted their target price on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $308.17.

Insider Buying and Selling

In related news, EVP Shannon Parisotto sold 2,156 shares of the business’s stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,655,578.87. The trade was a 30.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the transaction, the director directly owned 1,438 shares in the company, valued at approximately $410,175.12. This represents a 28.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 63,352 shares of company stock worth $20,291,281 in the last quarter. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Trading Down 0.9%

Shares of NYSE CRL opened at $342.81 on Thursday. Charles River Laboratories International, Inc. has a 1-year low of $146.20 and a 1-year high of $379.63. The company has a market cap of $16.43 billion, a PE ratio of 376.71, a P/E/G ratio of 3.13 and a beta of 1.36. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.76. The company has a 50-day moving average of $309.32 and a two-hundred day moving average of $227.05.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.97 by $0.12. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The company had revenue of $982.73 million for the quarter, compared to analyst estimates of $960.36 million. During the same period in the prior year, the business earned $2.43 earnings per share. Charles River Laboratories International’s quarterly revenue was down 2.2% on a year-over-year basis. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.